eligibility_summary
Adults (≥18) with confirmed locally advanced/metastatic soft tissue sarcoma (C1: escalation post-standard failure, expansion treatment‑naive) or osteosarcoma (C2: post-standard failure), ≥1 extracranial measurable lesion (RECIST), tumor tissue, ECOG 0–1, life ≥12 wks, contraception, consent. Exclude prior B7‑H3, TOP1i, PD‑L1 (C2), intolerance to anlotinib/anthracyclines/PD‑L1, recent chemo/biologic/radiation/surgery, other malignancy, organ/cardiac dysfunction, uncontrolled disease/infection/bleeding, neuropathy/psychiatric disorders, pregnancy/lactation, severe hypersensitivity, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
ARTEMIS-103 (Phase 1b) tests HS-20093 combinations in advanced osteosarcoma and soft tissue sarcoma. HS-20093 is a fully humanized IgG1 antibody-drug conjugate targeting B7-H3 (CD276) highly expressed on sarcoma, it binds B7-H3 on tumor cells and delivers a cytotoxic payload to induce cell death. Combinations: anlotinib (oral multi-target TKI of VEGFR/PDGFR/FGFR/c-KIT, anti-angiogenic), epirubicin (anthracycline, DNA intercalation and topoisomerase II inhibition), and adebrelimab (anti–PD-L1 monoclonal antibody, immune checkpoint blockade). Targets/pathways: B7-H3+ tumor cells, VEGF-driven tumor vasculature, tumor DNA replication (Topo II), and the PD-1/PD-L1 axis to enhance T-cell activity.